Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
M.D. Anderson Cancer Center
With
Millennium Pharmaceuticals, Inc.
Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib was administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days for a maximum of six cycles.
Age
17–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
INCLUSION:
Relapsed or Refractory B cell lymphoma.
Zubrod status \</= 3.
Measurable disease.
No anti-cancer treatment within past 3 weeks.
HIV negative.
No active CNS lymphoma.
No serious intercurrent illness, active infections or cancer except basal cell carcinoma of the skin or in situ cervical carcinoma.
You may not be if
No pregnancy \& age bearing females must be practicing adequate contraception.
Age \> 16.
EXCLUSION:
Patients with platelets \<30x10(9)/L within 14 days before enrollment.
Patients with ANC\<1.0 x10(9)/L within 14 days before enrollment.
Patients with peripheral neuropathy \>/= grade 3 within 14 days before enrollment.
